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We describe a case of 13-year-old female with intermittent asthma who developed lactic acidosis and
diastolic hypotension after receiving intermittent albuterol nebulizer treatment. She presented to the
emergency department (ED) with sudden onset of shortness of breath and chest pain. She received two
albuterol nebulizer treatments at home without symptomatic relief. She was treated in the ED with
intermittent albuterol nebulization for a total of 22.5 mg over the next 5 hours. A decrease in diastolic
blood pressure from 60 mmHg to 40 mmHg was noted after the treatment. Blood lactate level was
5.9 mmol/L. She recovered from it and was discharged to home but she had recurrence of shortness of
breath and presented to the ED two days later. She was treated with albuterol nebulization for a total of
17.5 mg over the next two and half hours and developed diastolic hypotension again, as low as 30 mm
Hg. After discontinuation of albuterol nebulization, her BP normalized. Cardiopulmonary and metabolic
side effects of continuous albuterol therapy have been reported in the recent medical literature. Our
patient, however, developed these adverse effects on intermittent albuterol nebulizer treatment. It is
important for the pediatrician to recognize the adverse effects of b2-agonist therapy to avoid carrying out
extensive workup for hypotension and hyperlactatemia prolonging hospital stay.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Nebulized albuterol is used widely for asthma patients during
asthma exacerbation and it is deemed safe for both intermittent
and continuous administration. Cardiopulmonary and metabolic
side effects have been noted with continuous albuterol therapy in
the recent medical literature. In pediatric patients in the emergency
department or hospitalized, these side effects can be more pro-
nounced with repeated dosing of albuterol. It is important for the
pediatricians to recognize the side effects of b2-agonist therapy in
order to manage the patients appropriately. We report a case of a
13-year-old girl with asthma, who required Pediatric Intensive Care
Unit (PICU) admission for low diastolic blood pressure refractory to
ﬂuid therapy after receiving intermittent b2-agonist nebulization.
2. Case presentation
A 13-year-old female with intermittent asthma presented to the
emergency department (ED) with sudden onset of shortness of. George).
Ltd. This is an open access article ubreath and chest pain.
She received two albuterol nebulizer treatments at home
without symptomatic relief before coming to the ED. Her vital signs
were respiratory rate (RR) of 28e36/min, blood pressure (BP) of 99/
60 mm Hg (within normal range for her age and height of 160 cm),
temperature of 99.8 F, pulse of 88/min, and oxygen saturation of
99% on room air. Nowheezing was heard on auscultation. In light of
the tachypnea and history of asthma, she was treated for acute
asthma exacerbation with repeated intermittent nebulized albu-
terol, 22.5 mg in 5 h, and dexamethasone 10 mg intravenously (IV).
She reported slight improvement in her symptoms. Her repeat BP
was 90/40 mm Hg after receiving 22.5 mg of nebulized albuterol
over 5 hours in the ED. She was administered one liter of normal
saline (NS) bolus. Arterial blood gas revealed pH of 7.22, pCO2 of
40.9 mm Hg, pO2 of 52.3 mm Hg, oxygen saturation of 80.3%, HCO3
of 16.2 mEq/L, base excess of 9.7, and lactate level of 5.9 mmol/L
(normal range 0.5e2.2). Basic metabolic panel (BMP) revealed Na
142 mmol/L, K 3.2 mmol/L, Cl 106 mmol/L, CO2 15 mmol/L, BUN
14mg/dl, and creatinine 0.72mg/dl, with an anion gap of 21. Patient
was admitted to the pediatric ward ten hours after initial presen-
tation with BP of 103/44 mm Hg. Nebulized albuterol 2.5 mg was
continued every two hours for two more doses. 14 h after initialnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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72/44mmHg and a pulse of 120 beats per minute (normal for age is
48e110). Patient was then administered a second one liter bolus of
NS and was transferred to the Pediatric Intensive Care Unit (PICU).
In the PICU, she received another one liter bolus of NS and was
started on continuous nebulization of albuterol 5 mg/h for one
hour. She was then noted to be free of wheezing and her symptoms
were thought to be related to panic attack. Albuterol was dis-
continued and IV ﬂuids were continued at her maintenance rate.
Within one hour of discontinuation of nebulized albuterol, her BP
normalized at 103/59 mm Hg and her dizziness resolved. It was
thought that her shortness of breath was most likely secondary to
anxiety. Her electrocardiogram and echocardiogram were normal
and repeat lactate was 2.9 mmol/L before she was discharged to
home the following day.
She felt ﬁne for the next two days after discharge, and then she
suddenly started to complain of chest tightness and non-radiating
midsternal chest pain of 8/10 intensity, associated with tachypnea
and a feeling of “not getting any air into my lungs” that was
aggravated by deep breathing. In the ED, her vital signs were RR of
26e30/min, pulse of 100/min, BP of 128/78 mm Hg, temperature of
99 F, and oxygen saturation of 98% on room air. She was treated for
status asthmaticus with intermittent nebulized albuterol 17.5 mg
over the next two and half hours, IV magnesium sulfate 2 g along
with one liter bolus of NS, and IV solumedrol 60 mg. She was
admitted to the pediatric ward and was treated with nebulized
albuterol every two hours for three times. Her BPwas 90/30mmHg
on arrival at the pediatric ward, and it was 108/37, 98/43, 99/43, 90/
34 and 78/32mmHg in the next 3 h. Her BP failed to respond to two
additional one liter boluses of NS, and she was transferred to the
PICU. In the PICU, she was free of wheezing and nebulized albuterol
was discontinued. Her BP was 96/50 mm Hg 90 min after discon-
tinuation of nebulized albuterol. In the next 24 h, her BP normal-
ized and she was transferred back to the ward, where her BP
remained above 90/50 mmHg for the remainder of her hospital
stay. She was discharged to home after 24 h of observation without
IV ﬂuids. Lactic acid level was not determined during the second
admission.
3. Discussion
Albuterol is a direct acting sympathomimetic agent used for its
bronchodilator effect on b2-receptors of the lungs [1]. Mild tachy-
cardia is commonwhen patients are treated with b2-agonist. Other
cardiovascular adverse effects of b-agonists are QT interval pro-
longation in the electrocardiogram, hypertension, and rarely, car-
diac ischemia and arrhythmias [2]. The mechanism of hypotension
after beta agonist therapy is thought to be secondary to its effect on
systemic vascular resistance and peripheral vasodilation [3].
Tachycardia may result from dilation of peripheral vasculature that
reduces venous return, which results in sympathetic nervous sys-
tem reﬂexes and increased inotropic and chronotropic effects [2].
Sarnaik et al. demonstrated that diastolic hypotension occurred in
56% of children transported to the hospital for respiratory distress
who received at least 10 mg of nebulized albuterol per hour and
98% of children with diagnosis of status asthmaticus who had
received at least 10 mg of nebulized albuterol per hour and had
measurement of troponin level. Diastolic hypotension and tachy-
cardia were associated with elevated troponin levels, indicative of
possible myocardial injury [4]. A similar study by Wisecup et al.,
illustrated a dose-dependent diastolic hypotension on continuous
albuterol nebulization therapy in 90% of patients admitted to pe-
diatric intensive or intermediate care units for management of
status asthmaticus [4]. The combination of tachycardia and dia-
stolic hypotension can be detrimental to myocardial perfusion.With tachycardia, shortening of diastolic duration can decrease the
blood perfusion to the sub-endocardium [5,6]. With increased
myocardial oxygen demand coupled with decreased coronary
perfusion pressure and decreased diastolic time fraction may result
in decreased myocardial oxygen supply to meet the demand.
Lactic acidosis is a well-established phenomenon in patients
with severe asthma and has been hypothesized, by some, to result
from inadequate oxygen delivery to the respiratory muscles, the
diaphragm, to meet an elevated oxygen demand [7]. During a se-
vere asthma attack, hypoxemia alone may lead to what is known as
“type A” lactic acidosis, which can occur in poor tissue perfusion,
shock, or hypoxia. On the other hand, “type B” lactic acidosis occurs
from decreased lactate metabolism in the absence of tissue hypo-
perfusion. Type A and B lactic acidosis can be distinguished by the
ratio of lactate to pyruvate concentrations in the blood [7]. In type A
the ratio is usually above 25:1. In a PICU study byMeerk et al. of the
105 pediatric asthma patients who received frequent or continuous
albuterol nebulizations, eighty-seven (83%) children had lactate
>2.2 mmol/L and 47 (45%) had lactate >5 mmol/L. Lactate/pyruvate
ratios were determined in 16 patients. Lactate/pyruvate ratio was
<10 in three patients; 10e25 in 11; >25 in one and indeterminate in
one patient. They concluded that type B lactic acidosis was more
common in patients receiving frequent albuterol nebulization [7].
Another retrospective study also showed similarly high number of
patients developing elevated lactic acid after beta agonist inhala-
tion or IV therapy for asthma. Of 75 pediatric patients who had
asthma exacerbation and were treated with nebulized or intrave-
nous albuterol, 55 patients had lactate level measured; 39 patients
(71%) had lactic acidosis with lactate level >2.2 mmol/L, and 12
(22%) had lactate level >5 mmol/L [8].
The mechanisms by which beta-agonists may cause lactic
acidemia are many. Stimulation of b-adrenoreceptors increases
plasma glucose concentrations, thus increasing substrate for
glycolysis. The end product of glycolysis, pyruvate can then diffuse
into the mitochondria and metabolized to carbon dioxide by
another, more energy-efﬁcient metabolic pathway, the Krebs cycle.
If the pathway is overwhelmed, the excess pyruvate is converted to
lactic acid by pyruvate dehydrogenase complex. Stimulation of b
adrenoceptors also increases lipolysis and b2 stimulation appears to
increase lipolysis to a greater degree than b1 stimulation. Increased
free fatty acids inhibit conversion of pyruvate to acetyl-coenzyme A
with consequent increases in lactic acid. Thus, a number of mech-
anisms may play role in lactic acidemia in patients with asthma
receiving nebulized or IV b2-agonists, usually in high doses. Finally,
glucocorticoids and sometimes theophylline used concomitantly
with beta-agonist inhalants in patients with obstructive airways
disease increase the level of intracellular cAMP and may enhance
the sensitivity of b-receptors to b-adrenergic agents that may
further amplify the above described event [9]. As our patient did
not receive high dose of continuous albuterol nebulization as part
of her ED management of asthma (calculated as approximately
4.5 mg/h for 5 h in the ED during the initial hospitalization and
7 mg/h for two and half hours in the ED during the second hospi-
talization), the cause of her diastolic hypotension is not obvious.
This could be due to the peripheral vasodilation impeding venous
return to heart causing diastolic hypotension.
Theremay have been other causes of hypotension in our patient,
such as postural orthostatic hypotension, relative dehydration, or
due to magnesium sulfate she received in the ED on second
admission; however, the prolonged hypotension does not explain
the magnesium sulfate induced hypotension. Her hydration status
was adequate. According to Naranjo's Adverse Drug Reaction (ADR)
scale for this case, the score was 6, indicating probable cause of
adverse reaction to albuterol (>9 ¼ deﬁnite ADR, 5e8 ¼ probable
ADR,1e4¼ possible ADR 0¼ doubtful ADR) [10]. The rapid reversal
T.A. Saadia et al. / Respiratory Medicine Case Reports 16 (2015) 89e91 91of hypotension and lactic acidosis after discontinuation of albuterol
is suggestive of the albuterol as the culprit for both lactic acidosis
and hypotension. It is also important to recognize that in the
asthmatic patient treated with albuterol, the acidotic state may
worsen tachypnea and mislead the physician to increase albuterol
treatments, contributing to worsening of cardiovascular adverse
events and lactic acidosis.
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